Diana DeGette actually said...

We need a full panoply of investment in the research, the basic science, the drug discovery and drug development that lasts.

opening statement

The goal of the biopharmaceutical accelerator will be in collaboration with our partners at NIAID.

The bacterium's resistance to colistin is particularly concerning because in this country physicians use colistin as the treatment of last r...